Hmga1 is differentially expressed and mediates silencing of the CD4/CD8 loci in t cell lineages and leukemic cells

Cancer Science

Volumn 103, Issue 3, 2012, Pages 439-447

  Xi, Yang ^a   Watanabe, Sugiko ^a   Hino, Yuko ^a   Sakamoto, Chiyomi ^a   Nakatsu, Yuko ^a   Okada, Seiji ^a   Nakao, Mitsuyoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL NUCLEUS DNA; GREEN FLUORESCENT PROTEIN; HIGH MOBILITY GROUP A1A PROTEIN; HYBRID PROTEIN; PROTEIN P21; PROTEIN P27;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; DOWN REGULATION; GENE LOCUS; GENE SILENCING; HETEROCHROMATIN; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; T LYMPHOCYTE; TRANSCRIPTION INITIATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; LEUKEMIA; LEUKEMIA CELL LINE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; GENE SILENCING; HMGA1A PROTEIN; HUMANS; JURKAT CELLS; LEUKEMIA; MICE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84859731073     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02159.x     Document Type: Article

References (46)

1. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol 2002; 2: 162-73.
2. Cedar H, Bergman Y. Immunology Epigenetics of haematopoietic cell development. Nat Rev Immunol 2011; 11: 478-88.
3. Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev Genet 2000; 1: 57-64.
4. Krangel MS. T cell development: better living through chromatin. Nat Immunol 2007; 8: 687-94.
5. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 2010; 463: 474-84.
6. Catez F, Hock R. Binding and interplay of HMG proteins on chromatin: lessons from live cell imaging. Biochim Biophys Acta 2010; 1799: 15-27.
7. Reeves R. Nuclear functions of the HMG proteins. Biochim Biophys Acta 2010; 1799: 3-14.
8. Giancotti V, Berlingieri MT, DiFiore PP, Fusco A, Vecchio G, Crane- Robinson C. Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. Cancer Res 1985; 45: 6051-7.
9. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990; 265: 8573-82.
10. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001; 277: 63-81.
11. Fashena SJ, Reeves R, Ruddle NH. A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation. Mol Cell Biol 1992; 12: 894-903.
12. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992; 27: 777-89.
13. Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 1995; 83: 1091-100.
14. John S, Reeves RB, Lin JX et al. Regulation of cell-type-specific interleukin-2 receptor alpha-chain gene expression: potential role of physical interactions between Elf-1, HMG-I(Y), and NF-kappa B family proteins. Mol Cell Biol 1995; 15: 1786-96.
15. Reeves R, Wolffe AP. Substrate structure influences binding of the nonhistone protein HMG-I(Y) to free nucleosomal DNA. Biochemistry 1996; 35: 5063-74.
16. Amirand C, Viari A, Ballini JP et al. Three distinct sub-nuclear populations of HMG-I protein of different properties revealed by co-localization image analysis. J Cell Sci 1998; 111: 3551-61.
17. Brocher J, Vogel B, Hock R. HMGA1 down-regulation is crucial for chromatin composition and a gene expression profile permitting myogenic differentiation. BMC Cell Biol 2010; 11: 64.
18. Chiappetta G, Avantaggiato V, Visconti R et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996; 13: 2439-46.
19. Fedele M, Fidanza V, Battista S et al. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 2006; 66: 2536-43.
20. Xu Y, Sumter TF, Bhattacharya R et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004; 64: 3371-5.
21. Fedele M, Pentimalli F, Baldassarre G et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005; 24: 3427-35.
22. Battista S, Pentimalli F, Baldassarre G et al. Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 2003; 17: 1496-8.
23. Wood LJ, Mukherjee M, Dolde C. EHMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000; 20: 5490-502.
24. Pierantoni GM, Agosti V, Fedele M et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003; 372: 145-50.
25. Akaboshi S, Watanabe S, Hino Y et al. HMGA1 is induced by Wnt/b-catenin pathway and maintains cell proliferation in gastric cancer. Am J Pathol 2009; 175: 1675-85.
26. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010; 1799: 48-54.
27. Ueda Y, Watanabe S, Tei S, Saitoh N, Kuratsu J, Nakao M. High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. Cancer Sci 2007; 98: 1893-901.
28. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 2006; 13: 1554-63.
29. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia 2002; 16: 1069-85.
30. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009; 174: 854-68.
31. Aoto T, Saitoh N, Sakamoto Y, Watanabe S, Nakao M. Polycomb group protein-associated chromatin is reproduced in post-mitotic G1 phase and is required for S phase progression. J Biol Chem 2008; 283: 18905-15.
32. Delaire S, Huang YH, Chan SW, Robey EA. Dynamic repositioning of CD4 and CD8 genes during T cell development. J Exp Med 2004; 200: 1427-35.
33. Merkenschlager M, Amoils S, Roldan E et al. Centromeric repositioning of coreceptor loci predicts their stable silencing and the CD4/CD8 lineage choice. J Exp Med 2004; 200: 1437-44.
34. Kieffer LJ, Greally JM, Landres I et al. Identification of a candidate regulatory region in the human CD8 gene complex by colocalization of DNase I hypersensitive sites and matrix attachment regions which bind SATB1 and GATA-3. J Immunol 2002; 168: 3915-22.
35. Huth JR, Bewley CA, Nissen MS et al. The solution structure of an HMGI(Y)-DNA complex defines a new architectural minor groove binding motif. Nat Struct Biol 1997; 4: 657-65.
36. Sengupta S, Shimamoto A, Koshiji M et al. Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 2005; 24: 1738-48.
37. Sgarra R, Zammitti S, Lo Sardo A et al. HMGA molecular network: from transcriptional regulation to chromatin remodeling. Biochim Biophys Acta 2010; 1799: 37-47.
38. Collins A, Littman D, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 2009; 9: 106-15.
39. Taniuchi I, Osato M, Egawa T et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002; 111: 621-33.
40. Chi TH, Wan M, Zhao K et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature 2002; 418: 195-9.
41. Kioussis D, Ellmeier W. Chromatin and CD4, CD8A and CD8B gene expression during thymic differentiation. Nat Rev Immunol 2002; 2: 909-19.
42. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7: 899-910.
43. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10: 5502-9.
44. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551-65.
45. Crist WM, Shuster JJ, Falletta J et al. Clincial feathres and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 1988; 72: 1891-7.
46. Uchun FM, Gaynon PS, Sense MG et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a children's cancer group study. J Clin Oncol 1997; 15: 2214-21.